ALFA Finder
India's fastest NSE & BSE filing alerts on Telegram, filtered to the stocks you hold
Telegram alerts
alfafinder.com →
ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
12 announcements with these filters
Alembic Pharmaceuticals received USFDA final approval for its generic Olopatadine Hydrochloride Ophthalmic Solution 0.7% ANDA. The product's US market is estimated at $20 million, per IQVIA.
Alembic Pharmaceuticals Limited has updated its list of Key Managerial Personnel authorised to determine materiality and make stock exchange disclosures. This update follows a board meeting held on November 4, 2026.
Alembic Pharmaceuticals expanded its strategic collaboration with DifGen Pharmaceuticals to commercialize over 20 complex generic products in the US. The portfolio targets a US$5 billion market.
Q2 FY27 revenue ₹26.03bn (+36% YoY), PAT ₹3.35bn (+81%), EBITDA margin 22% (+520bps). US formulations led growth (+77%).
Alembic Pharmaceuticals reported Q2 FY27 revenue growth of 36% to ₹2,603 Crore. Net profit surged 81% to ₹335 Crore, driven by exceptional US business performance.
Alembic Pharmaceuticals Ltd reported revenue from operations of ₹2,604 Cr (+36.3% YoY) and net profit of ₹335.2 Cr (+81.5% YoY) for Q2 FY27.
Alembic Pharmaceuticals scheduled its board meeting for November 4, 2026, to consider unaudited Q1/H1 FY27 results. Trading window re-opens 48 hours post-declaration.
Alembic Pharmaceuticals received USFDA final approval for Valganciclovir for Oral Solution, 50 mg/mL. This adds to its cumulative 247 USFDA ANDA approvals.
Alembic Pharmaceuticals' subsidiary, Alembic Global Holding SA, incorporated a new wholly-owned subsidiary, Alvesta Pharmaceuticals FZCO, in the UAE for Rs. 0.26 Crore.
Alembic Pharmaceuticals' wholly-owned subsidiary, Alembic Global Holding SA, incorporated a new step-down subsidiary, Alvesta Pharmaceuticals FZCO, in Dubai for AED 1 Lakh (approx. ₹0.23 Crore).
Alembic Pharmaceuticals received USFDA final approval for Ciprofloxacin and Dexamethasone Otic Suspension USP. This drug is therapeutically equivalent to the reference product Ciprodex Otic Suspension.
The company filed its quarterly shareholding pattern under SEBI Regulation 31(1)(b) for the period ended September 30, 2026.